Does SRRK pay a dividend?

The cached stock data on this page does not show a positive dividend yield for SRRK. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does SRRK stock do?

Clinical-stage biopharmaceutical company transitioning to commercialization, focusing on monoclonal antibodies targeting latent growth factor activation, led by Apitegromab for Spinal Muscular Atrophy (SMA).

What is SRRK stock's price target?

This cached page does not contain a precise model fair value for SRRK.

The TradeMates model verdict for SRRK is HOLD with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.

Is SRRK a good dividend stock?

SRRK is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

SRRK (SRRK) Stock Analysis

Q: Is SRRK stock a good investment?

The cached TradeMates AI model rates SRRK as HOLD with an investment score of 40/100. Scholar Rock is a clinical-stage biotech transitioning toward commercialization with lead asset Apitegromab. While Phase 3 trial success in SMA and consensus revenue projections ($140M in 2027, $650M in 2029) support valuation upside, heavy annual cash burn (-$300.6M in 2025) and insider selling signal near-term dilution risk. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Apitegromab's SMA commercial launch underpins long-term growth, but $300M annual cash burn creates near-term dilution risk.

Investment score: 40/100

Scholar Rock is a clinical-stage biotech transitioning toward commercialization with lead asset Apitegromab. While Phase 3 trial success in SMA and consensus revenue projections ($140M in 2027, $650M in 2029) support valuation upside, heavy annual cash burn (-$300.6M in 2025) and insider selling signal near-term dilution risk.

View the full interactive analysis